Noxxon Pharma AG is a Biopharma company pioneering the development of a new class of proprietary therapeutics called Spiegelmers, the chemically synthesized, non-immunogenic alternative to antibodies. NOXXON has a diversified portfolio of clinical stage Spiegelmer therapeutics:anti-CCL2/MCP-1 Spiegelmer® NOX-E36 for diabetic nephropathy / anti-CXCL12/SDF-1 Spiegelmer® NOX-A12 for oncology / anti-hepcidin Spiegelmer® NOX-H94 for anemia of chronic disease. The Spiegelmer platform provides the Company with powerful and unique discovery capabilities, which have generated a number of additional leads under preclinical investigation. Located in Berlin, Germany, NOXXON is a well financed mature biotech company with a strong syndicate of international investors, approx. 60 employees and a highly experienced management team.